TISSIUM Appoints Ruth Krestin as Vice President of Portfolio Strategy

PARIS–(BUSINESS WIRE)–TISSIUM, a private medical technology company developing biomorphic programmable polymers for tissue reconstruction, today announced the appointment of Ruth Krestin as Vice President of Portfolio Strategy at TISSIUM. In this role, she will be responsible for coordinating the verticals of TISSIUM and driving an effective strategy at the portfolio level.

Ms. Krestin joins TISSIUM with an extensive background of over 10 years of experience in the pharmaceutical industry. She comes from AstraZeneca, where she held various strategic leadership positions spanning R&D and commercial organizations. Most recently, she was Director of Competitive Intelligence, CVRM. His core expertise includes R&D operations, competitive intelligence, portfolio management and data analytics.

Prior to AstraZeneca, she spent 5 years in consulting at PwC and as a result brings strategy consulting methodologies and strong analytical skills to her new role at TISSIUM.

The addition of Ms. Krestin to TISSIUM’s leadership team is the latest in a series of high-level executive appointments as TISSIUM continues to expand its platform and prepare for commercialization. With a full executive suite spanning its operations across Europe and the United States, TISSIUM is staffed to support the expansion it anticipates over the next few years.

Christophe Bancel, CEO of TISSIUM, said: “We are delighted to have Ruth join the team as we continue to advance and grow the business. His strong background in consulting and quantitative analysis as well as his extensive experience in commercial and R&D functions will bring cross-functional alignment within the company and help us grow our various verticals as we move forward. We are confident that his expertise will enable him to make a significant contribution to advancing our platform as we remain focused on our goal of transforming tissue repair.

Ms. Krestin said, “I am honored to join TISSIUM in this important new role. TISSIUM has made incredible progress with its unique biopolymer platform and I look forward to contributing to the development and commercialization of its product portfolio. »


TISSIUM, a private medical technology company based in Paris, France and Boston, USA, is dedicated to the development and commercialization of products derived from its unique biopolymer platform. The company’s products will address multiple unmet clinical needs, including the repair and reconstruction of atraumatic tissue.

TISSIUM is developing a portfolio of products that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers, which form the foundation of the company’s technology platform. Currently, the company has a pipeline of seven products across three verticals, including sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process in a unique way. Additionally, the company is developing complementary delivery and activation devices to improve the performance and usability of its products.

TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013. For more information, please visit: www.TISSIUM.com and @TISSIUMtech.

Source link

Don F. Davis